Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Cartalax vs Larazotide
An educational, source-based comparison of Cartalax and Larazotide — how each peptide works, what it's researched for, and what to know before going deeper.
Tripeptide bioregulator researched for cartilage and joint support.
A synthetic tripeptide (Ala-Glu-Asp) in the Khavinson short-peptide family. Research suggests gene-expression modulation in chondrocytes and fibroblasts, supporting extracellular matrix synthesis and reducing cartilage degradation markers.
- Osteoarthritis and cartilage repair
- Joint mobility in aging
- Tendon and ligament integrity
- • Preclinical and Russian clinical data only.
- • Not FDA-approved.
An octapeptide zonulin antagonist that helps maintain intestinal tight junction integrity, reducing paracellular permeability triggered by gluten in celiac disease.
- Celiac disease (Phase 3 completed)
- Intestinal barrier function ('leaky gut' research)
- Environmental enteropathy
- • Not yet FDA-approved.
- • Investigational; physician oversight required.
Cartalax vs Larazotide — Key differences
- Class: Cartalax is classified as Musculoskeletal · Bioregulator, while Larazotide is Gastrointestinal · Barrier.
- Primary research focus: Cartalax — osteoarthritis and cartilage repair; Larazotide — celiac disease (phase 3 completed).
- Tag: Joint · Bioregulator vs Gut.